Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Alterity Therapeutics released its Q3 FY24 Quarterly Cash Flow Report, showcasing promising Phase 2 baseline data for ATH434-201 targeting biomarkers for slowing disease progression. The company raised A$5.25M, received a A$3.9M tax incentive refund, and ended the quarter with A$18.3M in cash. Operational updates include positive DMC review for ATH434-201, presentations at AAN, enrollment progress for ATH434-202, and promising results for ATH434 in Parkinson's disease. The bioMUSE study continues to provide valuable data on MSA progression.
Alterity Therapeutics presented new data at the World Orphan Drug Congress USA 2024 demonstrating the potential of ATH434 to treat Friedreich's Ataxia. The study showed that ATH434 acts as an iron chaperone, redistributing iron in the body, which could help reduce labile iron levels and slow disease progression. The unique iron-binding properties of ATH434 set it apart from traditional iron chelators, making it a promising treatment for neurodegenerative diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.